» Articles » PMID: 31370823

Pharmacotherapy for Mood and Anxiety Disorders in Older People with Intellectual Disability in Comparison with the General Population

Overview
Journal BMC Psychiatry
Publisher Biomed Central
Specialty Psychiatry
Date 2019 Aug 3
PMID 31370823
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: People with intellectual disability (ID) have high prevalence of psychiatric disorders, but even higher rates of prescription of psychotropic drugs.

Methods: Using Swedish national registers, we identified a group of older people with ID and diagnosis of mood disorders (ICD-10 codes F32-F39) and/or anxiety (ICD-10 code F4) during 2006-2012 (n = 587) and a referent group of people from the general population with the same diagnoses during the same time period (n = 434). For both groups, we collected information on prescription of anxiolytics, hypnotics and sedatives, antidepressants, and GABA-agonists.

Results: Among those with a diagnosis of anxiety, people with ID were more likely than those in the general population to be prescribed anxiolytics (Relative Risk 1.32 [95% Confidence Interval 1.19-1.46]) and GABA-agonists (1.10 [1.08-1.31]). Moreover, among those with anxiety but without mood disorders, ID was associated with increased prescription of antidepressants (1.20 [1.03-1.39]). Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID). Moreover, MSP ID was associated with increased prescription of GABA-agonists among those with anxiety (1.23 [1.10-1.38]).

Conclusions: The excess prescription of anxiolytics but not antidepressants may suggest shortages in the psychiatric health care of older people with intellectual disability and mood and anxiety disorders.

Citing Articles

Constipation among workers with depression/anxiety: a retrospective study using a claims database and survey data in Japan.

Karasawa Y, Nozawa K, Nomoto K, Fukudo S BMJ Open. 2024; 14(11):e083668.

PMID: 39566953 PMC: 11580253. DOI: 10.1136/bmjopen-2023-083668.


[Electroconvulsive therapy in people with intellectual disability].

Guhra M, Kreisel S, Zilles-Wegner D, Sartorius A, Sappok T, Freundlieb N Nervenarzt. 2024; 96(2):166-175.

PMID: 39240313 PMC: 11876283. DOI: 10.1007/s00115-024-01713-6.


The impact of employment on mental healthcare use among people with disability: distinguishing between part- and full-time employment.

Saxby K, Dickinson H, Petrie D, Kavanagh A, Aitken Z Scand J Work Environ Health. 2023; 49(8):598-609.

PMID: 37815158 PMC: 11402066. DOI: 10.5271/sjweh.4123.


Psychotropic drugs intake in people aging with intellectual disability: Prevalence and predictors.

Garcia-Dominguez L, Navas P, Verdugo M, Arias V, Gomez L J Appl Res Intellect Disabil. 2022; 35(5):1109-1118.

PMID: 35384179 PMC: 9545215. DOI: 10.1111/jar.12996.


Community-Based Support and Social Services and Their Association with Frailty Factors in Older People with Intellectual Disability and Affective and Anxiety Disorders: A Swedish National Population-Based Register Study.

El Mrayyan N, Bokberg C, Eberhard J, Ahlstrom G Community Ment Health J. 2021; 58(5):1000-1013.

PMID: 34750683 PMC: 9187569. DOI: 10.1007/s10597-021-00909-3.


References
1.
Scheifes A, Walraven S, Stolker J, Nijman H, Egberts T, Heerdink E . Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs. Res Dev Disabil. 2015; 49-50:13-21. DOI: 10.1016/j.ridd.2015.11.017. View

2.
Perry B, Cooray S, Mendis J, Purandare K, Wijeratne A, Manjubhashini S . Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey. J Intellect Disabil Res. 2018; 62(2):140-149. DOI: 10.1111/jir.12471. View

3.
Axmon A, Ahlstrom G, Hoglund P . Prevalence and treatment of diabetes mellitus and hypertension among older adults with intellectual disability in comparison with the general population. BMC Geriatr. 2017; 17(1):272. PMC: 5701367. DOI: 10.1186/s12877-017-0658-2. View

4.
Bowring D, Totsika V, Hastings R, Toogood S, McMahon M . Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study. J Intellect Disabil Res. 2017; 61(6):604-617. DOI: 10.1111/jir.12359. View

5.
Ji N, Findling R . Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry. 2016; 29(2):103-25. DOI: 10.1097/YCO.0000000000000233. View